Karyopharm Therapeutics宣布，已向美国食品药品监督管理局（FDA）提交了补充新药申请（sNDA），旨在寻求批准Xpovio®（塞利尼索，Selinexor）与Ruxolitinib的联合疗法，用于治疗骨髓纤维化患者。
Karyopharm Therapeutics宣布，已向美国食品药品监督管理局（FDA）提交了补充新药申请（sNDA），旨在寻求批准Xpovio®（塞利尼索，Selinexor）与Ruxolitinib的联合疗法，用于治疗骨髓纤维化患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.